Q: What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Constraint: The Molecule can be represented with the SMILES O=C1c2ccccc2OC=C(Cl)N1CCCCN1CC=C(c2ccccn2)CC1.
Answer: Phase 2 Clinical Trials
{#Question|Q!}: {quest#}
{#Constraint:|Description:|!} The {#Molecule|Compound|Chemical!} {#has the|can be represented with the!} {SMILES__description} {SMILES#}.
{#Answer|Result|Answer!}: {answ#}
O=C1c2ccccc2OC=C(Cl)N1CCCCN1CC=C(c2ccccn2)CC1
O=C1c2ccccc2OC=C(Cl)N1CCCCN1CC=C(c2ccccn2)CC1
3-chloro-4-[4-(4-pyridin-2-yl-3,6-dihydro-2H-pyridin-1-yl)butyl]-1,4-benzoxazepin-5-one
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Phase 2 Clinical Trials